|
1
|
Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye
QH, Wang L, Zhou J, Qiu SJ, Li Y, et al: A decade's studies on
metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol.
130:187–196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gu XQ, Zheng WP, Teng DH, Sun JS and Zheng
H: Impact of non-oncological factors on tumor recurrence after
liver transplantation in hepatocellular carcinoma patients. World J
Gastroenterol. 22:2749–2759. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Briggs MR, Kadonaga JT, Bell SP and Tjian
R: Purification and biochemical characterization of the
promoter-specific transcription factor, Sp1. Science. 234:47–52.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ishibashi H, Nakagawa K, Onimaru M,
Castellanous EJ, Kaneda Y, Nakashima Y, Shirasuna K and Sueishi K:
Sp1 decoy transfected to carcinoma cells suppresses the expression
of vascular endothelial growth factor, transforming growth factor
beta1, and tissue factor and also cell growth and invasion
activities. Cancer Res. 60:6531–6536. 2000.PubMed/NCBI
|
|
5
|
Jiang W, Jin Z, Zhou F, Cui J and Wang L
and Wang L: High co-expression of Sp1 and HER-2 is correlated with
poor prognosis of gastric cancer patients. Surg Oncol. 24:220–225.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang XB, Peng WQ, Yi ZJ, Zhu SL and Gan
QH: Expression and prognostic value of transcriptional factor sp1
in breast cancer. Ai Zheng. 26:996–1000. 2007.PubMed/NCBI
|
|
7
|
Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li
Q, Le X, Wang H, Yao J and Xie K: Therapeutic inhibition of Sp1
expression in growing tumors by mithramycin a correlates directly
with potent antiangiogenic effects on human pancreatic cancer.
Cancer. 110:2682–2690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pawlus MR and Hu CJ: Enhanceosomes as
integrators of hypoxia inducible factor (HIF) and other
transcription factors in the hypoxic transcriptional response. Cell
Signal. 25:1895–1903. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee H, Palm J, Grimes SM and Ji HP: The
Cancer Genome Atlas Clinical Explorer: a web and mobile interface
for identifying clinical-genomic driver associations. Genome Med.
7:1122015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carbajo-Pescador S, Ordoñez R, Benet M,
Jover R, García-Palomo A, Mauriz JL and González-Gallego J:
Inhibition of VEGF expression through blockade of Hif1α and STAT3
signalling mediates the anti-angiogenic effect of melatonin in
HepG2 liver cancer cells. Br J Cancer. 109:83–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sobin LH, Gospodarowicz MK and Wittekind
C: UICC: TNM Classification of Malignant Tumors (7th). Wiley-Liss.
New York, USA: 1–3. 2009.
|
|
12
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dinse GE and Lagakos SW: Nonparametric
estimation of lifetime and disease onset distributions from
incomplete observations. Biometrics. 38:921–932. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gill RD: Multistate life-tables and
regression models. Math Popul Stud. 3:259–276. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: A new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cao W, Xu X, Zhang J and Duan Y: Tumor
angiogenesis after heated lipiodol infusion via the hepatic artery
in a rabbit model of VX2 liver cancer. PLoS One. 8:e615832013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fusté M, Pinacho R, Meléndez-Pérez I,
Villalmanzo N, Villalta-Gil V, Haro JM and Ramos B: Reduced
expression of SP1 and SP4 transcription factors in peripheral blood
mononuclear cells in first-episode psychosis. J Psychiatr Res.
47:1608–1614. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Villa C, Ridolfi E, Fenoglio C, Ghezzi L,
Vimercati R, Clerici F, Marcone A, Gallone S, Serpente M, Cantoni
C, et al: Expression of the transcription factor Sp1 and its
regulatory hsa-miR-29b in peripheral blood mononuclear cells from
patients with Alzheimer's disease. J Alzheimers Dis. 35:487–494.
2013.PubMed/NCBI
|
|
19
|
Sun RC and Denko NC: Hypoxic regulation of
glutamine metabolism through HIF1 and SIAH2 supports lipid
synthesis that is necessary for tumor growth. Cell Metab.
19:285–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chiavarina B, Whitaker-Menezes D, Migneco
G, Martinez-Outschoorn UE, Pavlides S, Howell A, Tanowitz HB,
Casimiro MC, Wang C, Pestell RG, et al: HIF1-alpha functions as a
tumor promoter in cancer associated fibroblasts, and as a tumor
suppressor in breast cancer cells: Autophagy drives
compartment-specific oncogenesis. Cell Cycle. 9:3534–3551. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le
X, Li Q, Yao J and Xie K: Molecular basis of the synergistic
antiangiogenic activity of bevacizumab and mithramycin A. Cancer
Res. 67:4878–4885. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seznec J, Silkenstedt B and Naumann U:
Therapeutic effects of the Sp1 inhibitor mithramycin A in
glioblastoma. J Neurooncol. 101:365–377. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McDonald PC, Chafe SC and Dedhar S:
Overcoming hypoxia-mediated tumor progression: combinatorial
approaches targeting pH regulation, angiogenesis and immune
dysfunction. Front Cell Dev Biol. 4:272016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Badowska-Kozakiewicz AM, Budzik MP and
Przybylski J: Hypoxia in breast cancer. Pol J Pathol. 66:337–346.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ulivi P, Marisi G and Passardi A:
Relationship between hypoxia and response to antiangiogenic therapy
in metastatic colorectal cancer. Oncotarget. Apr 12–2016.(E-pub
ahead of print). doi: 10.18632/oncotarget.8712.
|
|
26
|
Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia
XF, Sun X, Li GG, Hu QD, Fu QH and Liang TB: Hypoxia-induced
epithelial-to-mesenchymal transition in hepatocellular carcinoma
induces an immunosuppressive tumor microenvironment to promote
metastasis. Cancer Res. 76:818–830. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Berghoff AS, Ilhan-Mutlu A, Wöhrer A,
Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Melchardt T, Dome
B, Heinzl H, et al: Prognostic significance of Ki-67 proliferation
index, HIF alpha index and microvascular density in patients with
non-small cell lung cancer brain metastases. Strahlenther Onkol.
190:676–685. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao H, Wu Y, Chen Y and Liu H: Clinical
significance of hypoxia-inducible factor 1 and VEGF-A in
osteosarcoma. Int J Clin Oncol. 20:1233–1243. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
dos Santos M, Mercante AM, Louro ID,
Goncalves AJ, de Carvalho MB, de Silva EH and da Silva AM:
HIF1-alpha expression predicts survival of patients with squamous
cell carcinoma of the oral cavity. PLoS One. 7:e452282012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wenger RH: Mammalian oxygen sensing,
signalling and gene regulation. J Exp Biol. 203:1253–1263.
2000.PubMed/NCBI
|
|
31
|
Hu TH, Huang CC, Lin PR, Chang HW, Ger LP,
Lin YW, Changchien CS, Lee CM and Tai MH: Expression and prognostic
role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular
carcinoma. Cancer. 97:1929–1940. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang Z, Huang L, Shen S, Li J, Lu H, Mo
W, Dang Y, Luo D, Chen G and Feng Z: Sp1 cooperates with Sp3 to
upregulate MALAT1 expression in human hepatocellular carcinoma.
Oncol Rep. 34:2403–2412. 2015.PubMed/NCBI
|
|
33
|
Guo X, Li D, Chen Y, An J, Wang K, Xu Z,
Chen Z and Xing J: SNP rs2057482 in HIF1A gene predicts clinical
outcome of aggressive hepatocellular carcinoma patients after
surgery. Sci Rep. 5:118462015. View Article : Google Scholar : PubMed/NCBI
|
